ATE323160T1 - Opioid antagonisten und verfahren zu deren anwendung - Google Patents

Opioid antagonisten und verfahren zu deren anwendung

Info

Publication number
ATE323160T1
ATE323160T1 AT96928209T AT96928209T ATE323160T1 AT E323160 T1 ATE323160 T1 AT E323160T1 AT 96928209 T AT96928209 T AT 96928209T AT 96928209 T AT96928209 T AT 96928209T AT E323160 T1 ATE323160 T1 AT E323160T1
Authority
AT
Austria
Prior art keywords
peptide
ofq
ligands
ofqr
methods
Prior art date
Application number
AT96928209T
Other languages
German (de)
English (en)
Inventor
Judith E Grisel
Jeffrey S Mogil
David K Grandy
James R Bunzow
Olivier Civelli
Rainer Klaus Reinscheid
Hans-Peter Nothacker
Frederick James Monsma
Original Assignee
Univ Oregon Health Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/514,451 external-priority patent/US5837809A/en
Application filed by Univ Oregon Health Sciences filed Critical Univ Oregon Health Sciences
Application granted granted Critical
Publication of ATE323160T1 publication Critical patent/ATE323160T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96928209T 1995-08-11 1996-08-12 Opioid antagonisten und verfahren zu deren anwendung ATE323160T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/514,451 US5837809A (en) 1995-08-11 1995-08-11 Mammalian opioid receptor ligand and uses
US08/553,058 US5821219A (en) 1995-08-11 1995-11-03 Opioid antagonists and methods of their use

Publications (1)

Publication Number Publication Date
ATE323160T1 true ATE323160T1 (de) 2006-04-15

Family

ID=27058205

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96928209T ATE323160T1 (de) 1995-08-11 1996-08-12 Opioid antagonisten und verfahren zu deren anwendung

Country Status (8)

Country Link
US (1) US5821219A (https=)
EP (1) EP0843726B1 (https=)
JP (1) JP3868494B2 (https=)
AT (1) ATE323160T1 (https=)
AU (1) AU728001B2 (https=)
CA (1) CA2229126A1 (https=)
DE (1) DE69636037D1 (https=)
WO (1) WO1997007212A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2206192A1 (en) 1996-06-13 1997-12-13 F. Hoffmann-La Roche Ag Modulation of lc132 (opioid-like) receptor function
EP0813065A3 (en) * 1996-06-13 1998-07-22 F. Hoffmann-La Roche Ag Modulation of LC132 (opioid-like) receptor function
AU8333998A (en) * 1997-07-15 1999-02-10 Novo Nordisk A/S New use of nociceptin
WO1999003880A1 (en) * 1997-07-15 1999-01-28 Novo Nordisk A/S Nociceptin analogues
US5929035A (en) * 1998-04-14 1999-07-27 Regents Of The University Of Michigan Methods of treating intestinal disorders
GB9815618D0 (en) * 1998-07-18 1998-09-16 Univ Manchester Treatment of dyskinesia
MA26659A1 (fr) 1998-08-06 2004-12-20 Pfizer Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
US6582457B2 (en) * 2001-02-15 2003-06-24 Radiant Medical, Inc. Method of controlling body temperature while reducing shivering
US6849449B2 (en) * 2001-03-01 2005-02-01 Regents Of The University Of Michigan Orphanin FQ receptor nucleic acids
JP2005502619A (ja) * 2001-07-02 2005-01-27 オメロス コーポレイション オピオイドレセプター様レセプター１アゴニストと交替でオピオイドレセプターアゴニストを投与することを含む、痛覚脱失を生成するための方法
US20030040479A1 (en) * 2001-07-02 2003-02-27 Omeros Corporation Rotational intrathecal analgesia method and device
WO2003030828A2 (en) * 2001-10-09 2003-04-17 Synvax, Inc. Nociceptin-based analgesics
WO2003093294A2 (en) * 2002-04-29 2003-11-13 Euro-Celtique S.A. Conformationally constrained peptides that bind the orl-1 receptor
AU2003257111A1 (en) * 2002-08-02 2004-02-23 Incyte Corporation Extracellular messengers
JP4712384B2 (ja) 2002-09-09 2011-06-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｏｒｌ−１受容体介在障害の治療に有用なヒドロキシアルキル置換１，３，８−トリアザスピロ［４．５］デカン−４−オン誘導体
CA2811272C (en) 2003-04-08 2016-12-20 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
US7173010B2 (en) * 2003-05-19 2007-02-06 Regents Of The University Of Michigan Orphanin FQ receptor
ES2714198T3 (es) 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
WO2006130416A2 (en) 2005-06-02 2006-12-07 Janssen Pharmaceutica, N.V. Novel 3-spirocyclic indolyl derivatives useful as orl-1 receptor modulators
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
US8703948B2 (en) 2006-11-28 2014-04-22 Janssen Pharmaceutica Nv Salts of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one
EP2565195B1 (en) 2007-03-29 2015-05-06 Wyeth LLC Peripheral opioid receptor and antagonists and uses thereof
PL2137191T3 (pl) 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
JP2010522756A (ja) 2007-03-29 2010-07-08 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 結晶形およびその使用
CA2683598C (en) 2007-04-09 2015-11-17 Janssen Pharmaceutica Nv 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression
WO2008142454A1 (en) 2007-05-22 2008-11-27 Prosidion Limited Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders
WO2009030962A1 (en) 2007-09-07 2009-03-12 Prosidion Limited Bicyclic aryl and heteroaryl receptor modulators
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
RU2492482C1 (ru) * 2012-10-08 2013-09-10 Игорь Петрович Папышев Способ диагностики причины смерти от интоксикации наркотическими веществами группы опиатов

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582820A (en) * 1982-12-23 1986-04-15 Research Corporation Orally administered biologically active peptides and proteins
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5017689A (en) * 1989-07-06 1991-05-21 Arizona Technology Development Corporation Dynorphin analogs specific for kappa opioid receptors
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US6235496B1 (en) * 1993-03-08 2001-05-22 Advanced Research & Technology Institute Nucleic acid encoding mammalian mu opioid receptor

Also Published As

Publication number Publication date
JP2001520634A (ja) 2001-10-30
JP3868494B2 (ja) 2007-01-17
US5821219A (en) 1998-10-13
EP0843726A1 (en) 1998-05-27
CA2229126A1 (en) 1997-02-27
EP0843726B1 (en) 2006-04-12
AU728001B2 (en) 2001-01-04
DE69636037D1 (de) 2006-05-24
AU6776996A (en) 1997-03-12
WO1997007212A1 (en) 1997-02-27

Similar Documents

Publication Publication Date Title
ATE323160T1 (de) Opioid antagonisten und verfahren zu deren anwendung
Heyman et al. Modulation of μ-mediated antinociception by δ agonists: characterization with antagonists
Swain et al. Endogenous opioids accumulate in plasma in a rat model of acute cholestasis
Lagrange et al. The potency of mu-opioid hyperpolarization of hypothalamic arcuate neurons is rapidly attenuated by 17 beta-estradiol
Suh et al. Intrathecal beta-funaltrexamine antagonizes intracerebroventricular beta-endorphin-but not morphine-induced analgesia in mice.
Narita et al. Evidence for the existence of the β-endorphin-sensitive “ε-opioid receptor” in the brain: The mechanisms of ε-mediated antinociception
Khroyan et al. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/μ-opioid receptor agonists
Kastin et al. Tyr-MIF-1 acts as an opiate antagonist in the tail-flick test
Barg et al. Evidence for the implication of phosphoinositol signal transduction in μ‐opioid inhibition of DNA synthesis
Suh et al. Delta but not mu-opioid receptors in the spinal cord are involved in antinociception induced by beta-endorphin given intracerebroventricularly in mice.
Romero et al. Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective μ/κ antagonist in the [35S]‐GTP‐γ‐S functional binding assay
Bhargava et al. Kappa opioid receptor activity in spontaneously hypertensive rats.
Varani et al. Nociceptin receptor binding in mouse forebrain membranes: thermodynamic characteristics and structure activity relationships
Varani et al. Pharmacology of [Tyr1] nociceptin analogs: receptor binding and bioassay studies
Gerstberger et al. Dynorphin 1–8 binds to opiate kappa receptors in the neurohypophysis
Beinborn et al. Minor modifications of a cholecystokinin-B/gastrin receptor non-peptide antagonist confer a broad spectrum of functional properties
Fujimoto et al. Clonidine, administered intracerebroventricularly in mice, produces an anti-analgesic effect which may be mediated spinally by dynorphin A (1–17)
Wu et al. Acute antinociceptive tolerance and asymmetric cross-tolerance between endomorphin-1 and endomorphin-2 given intracerebroventricularly in the mouse
Rothman et al. Ligand selectivity of cloned human and rat opioid mu receptors
EP0486520A4 (en) FOR KAPPA OPIOID RECEPTORS SPECIFIC DYNORPHINALALOG.
Han et al. Synergistic effect of cholecystokinin octapeptide and angiotensin II in reversal of morphine induced analgesia in rats
Dornand et al. Gastrin-CCK-B type receptors on human T lymphoblastoid Jurkat cells
Tsujii et al. Effects of food deprivation and high fat diet on opioid receptor binding in rat brain
Contreras et al. [3H] Naltrindole: a potent and selective ligand for labeling δ-opioid receptors
Jinsmaa et al. Potent in vivo antinociception and opioid receptor preference of the novel analogue [Dmt1] endomorphin-1

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties